Poor prognosis HMGA2^high PDXs are sensitive to PLK1 inhibitors in vivo. Summary of the treatment protocols and time point analysis for NSG mice transplanted with 2 million of 05H179 (A) or 09H057 (C) AML cells. Two weeks after transplantation, mice were treated with AraC (50 mg/kg, 5 days per week during 1 week), volasertib (10 mg/kg, 2 days per week during 4 weeks), or vehicle. BM aspiration was performed at indicated times. (B) Percentage of human CD45⁺ cells in BM at day 10 and 28 after AraC, volasertib, or vehicle treatment (n = 5, median is depicted; t test). (D) Percentage of human CD45⁺ (huCD45⁺) cells in BM at days 28, 78, and 94 after AraC, volasertib, or vehicle treatment (n = 5, median is depicted; t test). ns, not significant.